Since issuing the FAD, both Amgen and Merck have confirmed that they are wish to engage in further discussions about their submissions, which may have an impact on our recommendations. We have, therefore, decided to suspend the appeal stage of this appraisal. Both products are subject to the NICE/NHSE Cancer Drugs Fund transition arrangements.
We will work with both companies, the Assessment Group, and where necessary NHS England, on next steps.